| Literature DB >> 18806690 |
Ann Massie1, Anneleen Schallier, Birgit Mertens, Katia Vermoesen, Shiro Bannai, Hideyo Sato, Ilse Smolders, Yvette Michotte.
Abstract
Altered glutamate signaling is associated with Parkinson's disease. To study the involvement of the cystine/glutamate antiporter in the pathogenesis of Parkinson's disease, we developed new polyclonal antibodies recognizing xCT, the specific subunit of this antiporter. The striatal xCT protein expression level was investigated in a hemi-Parkinson rat model, using semiquantitative western blotting. We observed time-dependent changes after a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway with increased expression levels in the deafferented striatum after 3 weeks. Twelve weeks postlesion, expression levels returned to normal. These data suggest, for the first time, an involvement of the cystine/glutamate antiporter in determining the aberrant glutamate neurotransmission in the striatum of a parkinsonian brain.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18806690 DOI: 10.1097/WNR.0b013e328312181c
Source DB: PubMed Journal: Neuroreport ISSN: 0959-4965 Impact factor: 1.837